Cefotaxime (CAS 63527-52-6)

Cefotaxime, a third-generation cephalosporin antibiotic, has garnered significant attention in scientific research owing to its potent antibacterial properties. Its mechanism of action involves inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP-3 in Gram-negative bacteria. This leads to impaired peptidoglycan cross-linking, ultimately causing bacterial cell lysis and death. In research, cefotaxime has been instrumental in microbiology studies, serving as a crucial tool for bacterial culture and antibiotic susceptibility testing. Additionally, its efficacy against a wide range of Gram-negative pathogens, including Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, has made it indispensable for investigating bacterial resistance mechanisms and developing novel strategies. Furthermore, cefotaxime′s ability to penetrate the blood-brain barrier has facilitated its use in neuroscience research, particularly in studies exploring the role of bacterial infections in neurological disorders. Overall, cefotaxime continues to be a cornerstone in scientific investigations aimed at understanding bacterial physiology, pathogenesis, and antimicrobial resistance, providing invaluable insights into combating infectious diseases in various research domains.